Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed

BJU International

Volumn 100, Issue 4, 2007, Pages 755-759

  Pierorazio, Phillip M ^a   McKiernan, James M ^a   McCann, Tara R ^a   Mohile, Supriya ^a   Petrylak, Daniel ^a   Benson, Mitchell C ^a,b  

^a NewYork Presbyterian Hospital   (United States)

^b Herbert Irving Pavilion ^*  (United States)

Author keywords

Cytoreductive; Kidney neoplasm; Neoplasm metastasis; Outcomes; Renal cell carcinoma

Indexed keywords

INTERFERON; INTERLEUKIN 2;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER GRADING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; NEPHRECTOMY; PRIORITY JOURNAL; QUALITY OF LIFE; SOLITARY KIDNEY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

CARCINOMA, RENAL CELL; COHORT STUDIES; FEMALE; HUMANS; KIDNEY NEOPLASMS; LENGTH OF STAY; MALE; MIDDLE AGED; NEPHRECTOMY; QUALITY OF LIFE; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34548399499     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07108.x     Document Type: Article

References (24)

1. Patel NP, Lavengood RW. Renal cell carcinoma: natural history and results of treatment. J Urol 1978 119 : 722 6
2. Wagner JR, Walther MM, Linehan WM, White DE, Rosenberg SA, Yang JC. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol 1999 162 : 43 5
3. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 349 : 427 34
4. Couillard DR, deVere White RW. Surgery of renal cell carcinoma. Urol Clin North Am 1993 20 : 263 75
5. McCaffrey JA, Motzer RJ. What is the role of nephrectomy in patients with metastatic renal cell carcinoma? Seminars Oncol 1996 23 : xix xx
6. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996 335 : 865 75
7. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004 171 : 1071 6
8. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N Engl J Med 2001 345 : 1655 9
9. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon-α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001 358 : 966 70
10. Han KR, Pantuck AJ, Bui MH et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 2003 61 : 314 9
11. Pantuck AJ, Zisman A, Dorey F et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 2003 97 : 2995 3002
12. Rackley R, Novick A, Klein E, Bukowski R, McLain D, Goldfarb D. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 1994 152 : 1399 403
13. Slaton JW, Perrotte P, Balbay MD. Reassesment of the selection criteria for cytoreductive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 2000 163 (Suppl. 4 79
14. Bennett RT, Lerner SE, Taub HC, Dutcher JP, Fleischmann J. Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 1995 154 : 32 4
15. Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 1997 158 : 1691 5
16. Walther MM, Yang JC, Pass HI, Linehan WM, Rosenberg SA. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 1997 158 : 1675 8
17. Robertson CN, Linehan WM, Pass HI et al. Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol 1990 144 : 614 8
18. Leibovich BC, Cheville JC, Lohse CM et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 2005 174 1759 63
19. Leibovich BC, Han KR, Bui MH et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003 98 : 2566 75
20. Mani S, Todd MB, Katz K, Poo WJ. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 1995 154 : 35 40
21. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001 166 : 63 7
22. Irani J, Humbert M, Lecocq B, Pires C, Lefebvre O, Dore B. Renal tumor size: comparison between computed tomography and surgical measurements. Eur Urol 2001 39 : 300 3
23. Yaycioglu O, Rutman MP, Balasubramaniam M, Peters KM, Gonzalez JA. Clinical and pathologic tumor size in renal cell carcinoma; difference, correlation, and analysis of the influencing factors. Urology 2002 60 : 33 8
24. Cutalo M, Pierorazio PM, Katz M, Landman J, Benson MC, Olsson CA, McKiernan JM. Preoperative three-dimensional tumor volume predicts outcome in patients with renal cortical tumors. Presented at the 2007 American Urological Association Annual Meeting, Anaheim. Abstract 1296